Haemonetics (NYSE:HAE) Stock Price Down 6.2% – Here’s What Happened

Haemonetics Corporation (NYSE:HAE) fell 6.2% during trading on Tuesday . The company traded as low as $78.69 and last traded at $77.74. 197,216 shares changed hands during trading, a decline of 61% from the average session volume of 510,540 shares. The stock had previously closed at $82.92.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Closed acquisition of Vivasure expands Haemonetics’ portfolio into next‑generation percutaneous vessel‑closure devices, strengthening product pipeline and M&A‑driven growth thesis. Haemonetics Acquires Vivasure Medical
• Positive Sentiment: Analyst upgrade momentum: Barrington raised its price target to $93 with an “outperform” rating, signaling upside vs. current levels and providing analyst support for the stock. Barrington price target raise
• Positive Sentiment: Company fundamentals and guidance are constructive — recent quarterly beat and FY‑2026 EPS guidance (previously communicated) have improved the valuation story and prompted commentary about re‑rating HAE. How Recent Moves Are Rewriting The Haemonetics Story
• Neutral Sentiment: J.P. Morgan conference presentation transcript reiterated strategy and commercial priorities but contained no material surprise to materially change near‑term financials. J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Analyst coverage is broadly constructive but mixed in pace — data aggregators show several buy/outperform calls alongside more cautious views, so consensus is improving but not unanimous. Where Haemonetics Stands With Analysts
• Negative Sentiment: Deal cost and contingent payments: the Vivasure acquisition price (up to ~€185M including earnouts) increases near‑term cash outflow and integration risk, which can pressure free cash flow and weigh on the multiple until synergies are proven. Haemonetics to pay up to €185M for Vivasure
• Negative Sentiment: Market reaction: elevated trading volume and the stock’s pullback suggest profit‑taking and short‑term re‑rating risk despite positive fundamentals — investors appear focused on near‑term cash and execution risk post‑deal. Orchestra BioMed to Receive Up to $21M

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Mizuho increased their price target on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.40.

Haemonetics Stock Down 5.0%

The firm has a market cap of $3.69 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 1.55 and a beta of 0.29. The company has a 50-day simple moving average of $78.31 and a 200-day simple moving average of $65.92. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same period in the prior year, the business posted $1.12 earnings per share. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

A number of large investors have recently made changes to their positions in HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP bought a new position in Haemonetics in the 1st quarter worth about $216,000. United Services Automobile Association purchased a new position in shares of Haemonetics during the first quarter worth approximately $212,000. Empowered Funds LLC increased its position in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after acquiring an additional 9,051 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.